RESULTS: Our analysis revealed high levels of genetic variants in CMRGs, with 68.73% exhibiting copy number variations and 65.20% containing short variants that may disrupt protein function across individuals. Such variants can influence pharmacogenomics, genetic disease susceptibility, and other clinical outcomes. We observed significant differences in CMRG variation across populations, with individuals of African ancestry harboring the highest number of copy number variants and short variants compared to samples from other continents. Notably, 15.79% to 33.96% of short variants were exclusively detectable through long-read sequencing. While the T2T-CHM13 reference genome significantly improved the assembly of CMRG regions, thereby facilitating variant detection in these regions, some regions still lacked resolution.
CONCLUSIONS: Our results provide an important reference for future clinical and pharmacogenetic studies, highlighting the need for a comprehensive representation of global genetic diversity in the reference genome and improved variant calling techniques to fully resolve medically relevant genes.
结果:我们的分析显示CMRGs中存在高水平的遗传变异,68.73%表现出拷贝数变异,65.20%含有可能破坏个体蛋白质功能的短变体。这些变异可以影响药物基因组学,遗传性疾病易感性,和其他临床结果。我们观察到不同种群的CMRG变异存在显著差异,与其他大陆的样本相比,非洲血统的个体拥有最高数量的拷贝数变体和短变体。值得注意的是,15.79%至33.96%的短变体通过长读取测序是唯一可检测的。虽然T2T-CHM13参考基因组显着改善了CMRG区域的组装,从而促进这些区域的变异检测,一些地区仍然缺乏决心。
结论:我们的结果为未来的临床和药物遗传学研究提供了重要的参考,强调需要在参考基因组中全面代表全球遗传多样性,并改进变体调用技术以完全解析医学相关基因。